Cargando…

Metastatic Urothelial Carcinoma with Glandular Differentiation That Confirmed the Response by Autopsy Specimen to Second-Line mFOLFOX6 (Fluorouracil, Oxaliplatin, and Leucovorin) plus Bevacizumab Chemotherapy

The prognostic significance of glandular differentiation in urothelial carcinoma (UC) is controversial, and thus far there is no established treatment strategy against metastasis of glandular component. We describe here a case of metastatic UC with glandular differentiation that had histological dis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naiki, Taku, Etani, Toshiki, Naiki-Ito, Aya, Fujii, Kana, Ando, Ryosuke, Iida, Keitaro, Nagai, Takashi, Sugiyama, Yosuke, Nakagawa, Motoo, Kawai, Noriyasu, Yasui, Takahiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836210/ https://www.ncbi.nlm.nih.gov/pubmed/29515396 http://dx.doi.org/10.1159/000484597

Ejemplares similares

5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study
por: Hecht, J Randolph, et al.
Publicado: (2015)

A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma
por: Horimatsu, Takahiro, et al.
Publicado: (2017)

Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
por: Cunningham, D, et al.
Publicado: (2013)

Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) as secondline therapy for patients with advanced urothelial cancer
por: Zhang, Sheng, et al.
Publicado: (2016)

Laparoscopic radical surgery produces a good prognosis in an elderly patient with small Wilms’ tumor
por: Ota, Yuya, et al.
Publicado: (2019)

Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study
por: Emmanouilides, Christos, et al.
Publicado: (2007)

GPX2 promotes development of bladder cancer with squamous cell differentiation through the control of apoptosis
por: Naiki, Taku, et al.
Publicado: (2018)

Combination therapy with radiation and hyperthermia‐induced clinical complete response of small cell carcinoma of prostate
por: Kawai, Noriyasu, et al.
Publicado: (2022)

Experience with adjuvant chemotherapy for pseudomyxoma peritonei secondary to mucinous adenocarcinoma of the appendix with oxaliplatin/fluorouracil/leucovorin (FOLFOX4)
por: Chen, Chin-Fan, et al.
Publicado: (2008)

Interstitial lung disease in a patient treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) for metastatic colorectal cancer
por: Hannan, Liam M, et al.
Publicado: (2012)

A Case of Renal Primitive Neuroectodermal Tumor Confirmed by Fluorescence in situ Hybridization
por: Etani, Toshiki, et al.
Publicado: (2015)

Successful Treatment of Metastatic Anal Canal Adenocarcinoma with mFOLFOX6 + Bevacizumab
por: Matsunaga, Mototsugu, et al.
Publicado: (2016)

Metastasectomy as optimal treatment for late relapsing solitary brain metastasis from testicular germ cell tumor: a case report
por: Iida, Keitaro, et al.
Publicado: (2014)

Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial
por: Takahashi, Takao, et al.
Publicado: (2022)

Feasibility of Oxaliplatin, Leucovorin, and 5-Fluorouracil (FOLFOX-4) Chemotherapy in Heavily Pretreated Patients with Recurrent Epithelial Ovarian Cancer
por: Lee, Hee Jun, et al.
Publicado: (2013)

A Case of Metastatic Urothelial Carcinoma Treated with Pemetrexed as Third-Line Chemotherapy with Discussion and Literature Review
por: Iida, Keitaro, et al.
Publicado: (2015)

Inflammatory Myofibroblastic Tumor of the Urinary Bladder: A Case Report
por: Etani, Toshiki, et al.
Publicado: (2016)

NCL1, A Highly Selective Lysine-Specific Demethylase 1 Inhibitor, Suppresses Castration-Resistant Prostate Cancer Growth via Regulation of Apoptosis and Autophagy
por: Etani, Toshiki, et al.
Publicado: (2019)

Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C(3)) study
por: Nagasaka, Takeshi, et al.
Publicado: (2016)

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
por: Bendell, Johanna C., et al.
Publicado: (2019)

Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer
por: Conteduca, Vincenza, et al.
Publicado: (2018)

Complete surgical removal of multiple tumor lesions in malignant pheochromocytomas produces a good prognosis
por: Nozaki, Satoshi, et al.
Publicado: (2019)

Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)
por: Oki, Eiji, et al.
Publicado: (2019)

Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis
por: Buchler, Tomas, et al.
Publicado: (2014)

Luteolin suppresses bladder cancer growth via regulation of mechanistic target of rapamycin pathway
por: Iida, Keitaro, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer
por: Bai, Liangliang, et al.
Publicado: (2019)

NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect
por: Etani, Toshiki, et al.
Publicado: (2014)

Bacillus Calmette-Guerin therapy after the second transurethral resection significantly decreases recurrence in patients with new onset high-grade T1 bladder cancer
por: Iida, Keitaro, et al.
Publicado: (2016)

Nonpalpable testicular pure seminoma with elevated serum alpha-fetoprotein presenting with retroperitoneal metastasis: a case report
por: Iwatsuki, Shoichiro, et al.
Publicado: (2016)

Long-term survival of a patient with pulmonary metastatic urothelial carcinoma following metastasectomy
por: Hasebe, Kenichi, et al.
Publicado: (2018)

Role of HIKESHI on Hyperthermia for Castration-Resistant Prostate Cancer and Application of a Novel Magnetic Nanoparticle with Carbon Nanohorn for Magnetic Hyperthermia
por: Nagai, Takashi, et al.
Publicado: (2023)

Cardiac metastasis from colon cancer effectively treated with 5-fluorouracil, leucovorin, and oxaliplatin (modified FOLFOX6) plus panitumumab: a case report
por: Tsujii, Yoshiki, et al.
Publicado: (2017)

Pure Lymphoepithelioma-Like Carcinoma Originating from the Urinary Bladder
por: Nagai, Takashi, et al.
Publicado: (2016)

Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade
por: Nagai, Takashi, et al.
Publicado: (2018)

A pilot study of gemcitabine and paclitaxel as third-line chemotherapy in metastatic urothelial carcinoma
por: Naiki, Taku, et al.
Publicado: (2017)

Gemcitabine and docetaxel as second-line chemotherapy in elderly patients with metastatic urothelial carcinoma: a retrospective analysis
por: Naiki, Taku, et al.
Publicado: (2018)

UroVysion fluorescence in situ hybridization in urothelial carcinoma: a narrative review and future perspectives
por: Nagai, Takashi, et al.
Publicado: (2021)

A narrative review of peripheral blood parameters for urothelial carcinoma treated with systemic antitumor drugs
por: Nagai, Takashi, et al.
Publicado: (2023)

5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice
por: Yamai, Takuo, et al.
Publicado: (2022)

A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer
por: Gravalos, Cristina, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_kjf2tn38nluduttb7hp14haiv7